Phase 3 Readout
IRON: Phase 3 Topline: APOLLO: A Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin to Evaluate the Efficacy,
October 1, 2026 · bitopertin. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 1, 2026
- Company
- Disc Medicine, Inc. (IRON)
- Drug
- bitopertin
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: APOLLO: A Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin to Evaluate the Efficacy,
- Company
- Disc Medicine, Inc. (IRON)
- Drug
- bitopertin
- Indication
- Erythropoietic Protoporphyria (EPP); X-Linked Protoporphyria (XLP)